Does microwave interstitial hyperthermia prior to high-dose-rate brachytherapy change prostate volume or therapy plan parameters?

References

• Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol 2013;107:325–32
   PubMed Web of Science ®Google Scholar
• Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012;11:20–32
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, et al. Randomized trial of hyperthermia as an adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 1995;345:540–3
   PubMed Web of Science ®Google Scholar
• Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731–44
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez GD, Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119–25
   PubMed Web of Science ®Google Scholar
• Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: An update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys 2008;70:1176–82
   PubMed Web of Science ®Google Scholar
• Ryu S, Brown SL, Kim SH, Khil MS, Kim JH. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 1996;34:133–8
   PubMed Web of Science ®Google Scholar
• Maluta S, Dall’Oglio S, Romano M, Marciai N, Pioli F, Giri MG, et al. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study. Int J Hyperthermia 2007;23:451–6
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw AA, Raaymakers BW, Van Moorselaar RJ, Hofman P, Lagendijk JJ, et al. Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: Preliminary results. BJU Int 2004;93:36–41
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw JR, Van Gellekom MP, Van Der Hoeven J, De Graeff A, Van Moorselaar RJ, et al. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia 2003;19:402–13
   PubMed Web of Science ®Google Scholar
• Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, et al. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 2005;181:35–41
   PubMed Web of Science ®Google Scholar
• Kukiełka AM, Hetnał M, Brandys P, Walasek T, Dąbrowski T, Pluta E, et al. Interstitial hyperthermia of the prostate in combination with brachytherapy: An evaluation of feasibility and early tolerance. Strahlenther Onkol 2013;189:467–75
   PubMed Web of Science ®Google Scholar
• Kukiełka AM, Hetnał M, Dąbrowski T, Walasek T, Brandys P, Nahajowski D, et al. Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. Strahlenther Onkol 2014;190:165–70
   PubMed Web of Science ®Google Scholar
• Hurwitz MD, Kaplan ID, Hansen JL, Prokopios-Davos S, Topulos GP, Wishnow K, et al. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. Int J Hyperthermia 2005;21:649–56
   PubMed Web of Science ®Google Scholar
• Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: Long-term results from Dana-Farber Cancer Institute study 94–153. Cancer 2011;117:510–16
   PubMed Web of Science ®Google Scholar
• Żółciak-Siwińska A, Jonska-Gmyrek J, Staniaszek J, Piotrkowicz N, Michalski W. HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy: A phase I study. Int J Hyperthermia 2012;28:715–20
   PubMed Web of Science ®Google Scholar
• Żółciak-Siwińska A, Piotrkowicz N, Jonska-Gmyrek J, Nicke-Psikuta M, Michalski W, Kawczyńska M, et al. HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy – A phase III study. Radiother Oncol 2013;109:194–9
   PubMed Web of Science ®Google Scholar
• Kim Y, Hsu I-C, Lessard E, Vujic J, Pouliot JU. Dosimetric impact of prostate volume change between CT-based brachytherapy fractions. Int J Radiat Oncol Biol Phys 2004;59:1208–16
   PubMed Web of Science ®Google Scholar
• Kiffer JD, Schumer WA, Mantle CA, McKenzie BJ, Feigen M, Quong GG, et al. Impact of oedema on implant geometry and dosimetry for temporary high dose rate brachytherapy of the prostate. Australas Radiol 2003;47:172–6
   PubMedGoogle Scholar
• Waterman FM, Yue N, Corn BW, Dicker AP. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998;41:1069–77
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, Raaymakers BW, de Leeuw AAC, van de Kamer JB, van Moorselaar JA, Hobbelink MGG, et al. Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques. J Urology 2002;168:1597–602
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer, version 1.2014. Fort Washington, PA: NCCN, 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Emami B, Stauffer P, Dewhirst MW, Prionas S, Ryan T, Corry P, et al. RTOG quality assurance guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol Phys 1991;20:1117–24
   PubMed Web of Science ®Google Scholar
• Foster W, Cunha JA, Hsu IC, Weinberg V, Krishnamurthy D, Pouliot J. Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2011;80:85–90
   PubMed Web of Science ®Google Scholar
• Seppenwoolde Y, Kolkman-Deurloo I-K, Sipkema D, de Langen M, Praag J, Jansen P, et al. HDR prostate monotherapy – Dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 2008;86:114–19
   PubMed Web of Science ®Google Scholar
• Dinkla AM, Pieters BR, Koedooder K, van Wieringen N, van der Laarse R, Bel A. Prostate volume and implant configuration during 48 hours of temporary prostate brachytherapy: Limited effect of oedema. Radiat Oncol 2014;9:272
   PubMed Web of Science ®Google Scholar
• Scanlan KA. Sonographic artifacts and their origins. Am J Roentgenol 1991;156:1267–72
   PubMed Web of Science ®Google Scholar